Kornimate/medical-research-clean huggingface dataset:
echange: ehealth design to facilitate weight maintenance following initial weight loss

Conditions: Weight, Body

Summary: the aim of this study is to evaluate an ehealth intervention facilitating weight maintenance following initial weight loss during a 3-month trial (pilot test)

obesity rates are rapidly increasing and even with diets and interventions aiding weight loss, an alarmingly large percentage of people struggle to maintain the lost weight. in the face of obesity, weight maintenance is therefore arising as a major obstacle and new innovative approaches are called for. despite the fact that a substantial number of web-based diets, health and fitness focused interventions or "apps" already exist, few focus on weight maintenance, are research based or available post study. in addition, most have yet to show short- or long-term effect and few, if any, are developed together with users (e.g., patients, health care professionals). ehealth solutions may therefore be a "missing link" in supporting self-regulation and motivation for sustainable health behavior change and weight loss maintenance. the aim of this study is to evaluate a person-centered, evidence based interactive ehealth intervention facilitating weight maintenance following initial weight loss during a 3- month feasibility pilot trial.

Eligibility criteria:
inclusion criteria: * bmi 30 or more before weight loss * 8% weight reduction or more through conservative methods * aim to maintain weight after weight loss or prevent weight gain * understand and read the norwegian languague * can access the internet and own a smartphone exclusion criteria: * weight loss through surgery or medication * medication to support weight loss or maintenance

Keywords: weight maintenance
assisted suicide in switzerland

Conditions: Assisted Suicide

Summary: background: researchers want to learn more about how the swiss model of assisted suicide works. to do this, they have interviewed 25 swiss experts. the researchers will draw on research in the fields of ethics, law, and medicine to analyze the transcripts. objective: to describe the practice of assisted suicide in switzerland and to study how the policy is carried out, how the right-to-die societies work, and the ethical implications of the practice. eligibility: swiss experts in the field of assisted suicide design: the study includes 25 interviews that have already been conducted. the participants were: * academics * doctors and others in medical care * a government official * representatives of right-to-die societies. researchers will analyze the data using qualitative methods. two researchers will develop a coding scheme and code the texts and analyze the data.

switzerland is the only country in the world that enables assisted suicide by lay people, i.e., people who are not physicians. all other countries that have adopted aid-in-dying legislation require that a physician provides this assistance. this project probes the reasons for adopting this policy, and the advantages and the disadvantages of the swiss model at the end of life. are the swiss aid-in-dying volunteers able to provide well-informed assistance to patients in need? is the swiss model one to be followed by other nations? the project will focus on the work of the swiss aid-in-dying societies. the study draws on research in the fields of ethics, law and medicine. its novelty lies in incorporating different methods of analysis, reflecting on the right to die with dignity within a liberal framework that aims to respect fundamental human rights.

Eligibility criteria:
* inclusion/exclusion: the study includes 25 interviews with swiss experts that have been conducted. * gender: men 14, women 11 * backgrounds of interviewees: academics 14, physicians and other medical care 6, right to die associations 4, government official 1 * race and ethnicity: all white swiss. * age range: unknown, but all are adults. * no vulnerable populations.

Keywords: ethics switzerland end of life assisted death natural history
tamis-ipaa vs. lap-ipaa for ulcerative colitiis

Conditions: Ulcerative Colitis; Postoperative Complications; Ileal Pouch

Summary: the objective of this rct is to compare the postoperative outcome of transanal versus transabdominal minimally invasive proctectomy with ileal pouch-annal anastomosis in patients with ulcerative colitis.

theoritically, the advantge of tamis surgery over traditional trans-abdominal ipaa surgery incudes shorter operation time due to simulatous surgery transanlly and transabdominally, reduced operative difficulty in narrow male pelvis, less retained rectal cuff and less "dog-ear" formation. however, its adgange has not been proven in prospecitve randomized trials. the aim of current study is to compare the short and long-term postoperative outcome of transanal versus transabdominal minimally invasive proctectomy with ileal pouch-annal anastomosis in patients with ulcerative colitis.

Eligibility criteria:
inclusion criteria: * clincially and pathologically proven ulcerative colitis * aged 18-75 years * patients who will undergo proctectomy and ipaa surgery, incuding the first stage of two-stage surgery, or the second stage of three-stage or modified two-stage surgery * elective surgery * informed constent obtained. exclusion criteria: * a contraindication for minimally invasive surgery or tamis surgery * ileus or peritonitis * previous surgery in rectum * pregnancy * carcinogenesis of rectum, dysplasia or stricture of atz, or planned mucosectomy * patients with planned permnant ileostomy

Keywords: ulcerative colitiis ileal pouch anal anastomosis transanal minimally invasive surgery postoperative outcome
first in human study of cx-2051 in advanced solid tumors

Conditions: Solid Tumor, Adult

Summary: the purpose of this first-in-human study, ctmx-2051-101, is to characterize the safety, tolerability, and antitumor activity of cx-2051 in adult participants with advanced solid tumors.

the study is comprised of 2 parts. part 1 involves cx-2051 dose escalation to identify the maximum tolerated dose (mtd) of cx-2051. part 2 (dose expansion) will further assess safety and tolerability as well as preliminarily assess antitumor activity of cx-2051 in indication-specific expansion cohorts.

Eligibility criteria:
inclusion criteria: * metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy * eastern cooperative oncology group (ecog) performance status of 0-1 * measurable disease per recist v1.1 * consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue * additional inclusion criteria may apply exclusion criteria: * recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated * known active central nervous system (cns) involvement by malignancy * systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to c1d1 * previous treatment with antibody-drug conjugates (adcs) with topo-i inhibitor payload * major surgery (requiring general anesthesia) within 4 weeks prior to c1d1 * elevated baseline laboratory values * serious concurrent illness * pregnant or breast feeding * additional exclusion criteria may apply
how to prevent heart failure readmission by using lung impedance device (hope-hf study)

Conditions: Heart Failure Acute

Summary: the readmission of heart failure (hf) patients for exacerbation hf within 30-day is unmet goal. the mail reason for readmission is excessive accumulation of fluid in patient's lung. according our data (1,2) around 40% of hf patient have excessive lung fluid at discharge from hf hospitalization ("unacceptable" residual congestion on discharge). in other words, around 40% patients are discharged from hf hospitalization prematurely when they are not ready to be discharged. only 60% of hf patients are discharged from hf admission with "acceptable" level of residual pulmonary congestion (2). there are some techniques to assess "readiness" of hf patients for discharge. pulmonary congestion (lung fluid accumulation) may be assessed non-invasively by measurement brain natriuretic peptide (bnp), (3,4), by lung ultrasound (lus), (5-7) and by lung impedance (li) method (1,2). lus is operator depended technique. li and bnp techniques are most reliable methods (2) and easy to use.


Eligibility criteria:
inclusion criteria: * acute heart failure patients prior to hospital discharge exclusion criteria: * no cardiac resynchronization device implanted during current hospitalization * estimated glomerular filtrating rate (gfr) less than 30 ml/min
evaluation of adhexil safety and efficacy in prevention and/or reduction of adhesions in gynecological surgery

Conditions: Ovarian Cysts; Endometriosis; Adhesions

Summary: the objective of this study is to evaluate the safety and efficacy of adhexil™ in preventing and/or reducing post-operative adhesions in patients undergoing surgery involving the ovaries.

patients will be divided into two arms: 1) patients who will be treated in accordance with standard of care; 2) patients for which adhexil™ will be applied on one ovary and fallopian tube.

Eligibility criteria:
inclusion criteria: * female patients aged 18-45 years at screening. * patients undergoing elective laparoscopic surgery involving at least one adnexa. exclusion criteria: * pregnant (including ectopic pregnancy) or breastfeeding patient. * patients with a documented diagnosis of cancer. * patients with a lymphatic, hematologic or coagulation disorder. * patients with a known or suspected hypersensitivity to blood, blood products or any constituent of adhexil™. * patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants. * patients who have participated in another clinical study within 30 days of enrolment. * investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study.
quantification of arm non-use after a stroke

Conditions: Hemiplegia

Summary: reproducibility assessment of a quantitative measure of the amount of trunk compensation by kinematic analysis in a grasping task in stroke patients.this "maladaptive trunk compensation" is suspected to be underlined by "arm non-use" in some patients, since this abnormal movement impairs the ability of patients to correctly flex their shoulder and extend their elbow during grasping.


Eligibility criteria:
inclusion criteria: * · patient hemiparetic * hemiplegic patient * patient can perform a global task with the gripping limb exclusion criteria: * patient can not actively tender elbow of the affected limb, * patient who can not actively flex the shoulder of the affected limb, * patient with a passive extension deficit elbow\> 30 °, * patient with a shoulder flexion passive deficit\> 60 °, * patient with severe neglect * patient bearer severe cognitive impairment * a patient with aphasia understanding disorders
protective effect of n-acetylcysteine against from ototoxicity

Conditions: Hearing Loss, Extreme

Summary: peritonitis is currently one of the leading complications of continuous ambulatory peritoneal dialysis (capd). aminoglycosides and vancomycin are used in the treatment of capd peritonitis despite their potential risk for ototoxicity. nac is a molecule used in the treatment and prophylaxis of many diseases related to oxidative stress. the aim of this study was to examine whether ototoxicity due to antibiotics used in the treatment of capd peritonitis can be prevented by n-acetylcysteine

nac, a thiol-containing antioxidant because of this,we want to investigate antioxidant status.

Eligibility criteria:
inclusion criteria: * end-stage renal disease * undergoing continuous ambulatory peritoneal dialysis as a renal replacement therapy * developing the first continuous ambulatory peritoneal dialysis related peritonitis episode exclusion criteria: * being treated with aminoglycoside antibiotics and vancomycine within the previous 3 months * detection of mechanical occlusion of external ear * having signs of disturbed integrity of tympanic membrane on otoscopy or tympanometry * history of a continuous ambulatory peritoneal dialysis related peritonitis

Keywords: ototoxicity aminoglycoside vancomycine peritoneal dialysis peritonitis
effect of preoperative individualized education on anxiety and recovery.

Conditions: Education

Summary: researchers aim to investigate whether individualized preoperative education for patients is beneficial in reducing perioperative anxiety, promoting postoperative recovery, and enhancing postoperative quality of life. the educational content will cover aspects such as the surgery procedure, anesthesia, postoperative pain and anxiety management, recovery time, and any potential required treatments. all participants will be administered a questionnaire before the surgery to evaluate their specific concerns and fears. the intervention group will receive preoperative education through audio-visual materials followed by targeted preoperative counseling, while the control group will receive routine preoperative education.

patients who met the research criteria were consulted prior to surgery, during which the research objectives were explained, and written consent was obtained. following baseline assessment, patients were randomly allocated to either the individualized education group or the routine education group. sociodemographic information was collected through face-to-face interviews conducted in the ward. additionally, levels of anxiety and adverse events (sleep, pain, nausea, vomiting) were measured using the visual analog scale (vas) and hospital anxiety and depression scale (hads). patient anxieties regarding different aspects were assessed using specific concerns and fears scales. the intervention group received individualized educational interventions utilizing audiovisual materials. based on identified personalized educational needs, researchers administered individualized preoperative education to the intervention group in the ward. patients in the control group received only routine preoperative education from clinical nurses. the second assessment was conducted before patients were transferred to the operating room. anxiety levels and adverse events (preoperative sleep, pain, nausea, and vomiting) were assessed using hads and vas. postoperatively, pain, nausea, vomiting, and coughing were evaluated three times daily for the first three days (every 8 hours) using the visual analog scale (vas), and sleep was assessed daily using the athens insomnia scale (ais). chronic symptoms and quality of life were assessed at postoperative weeks 1, 2, 4, 12, 26, and 52. chronic cough was evaluated using the leicester cough questionnaire, and chronic pain was evaluated using the brief pain inventory. the european organization for research and treatment of cancer quality of life questionnaire-core 30 (eortc qlq-c30) and hads were used for continuous assessment of quality of life, anxiety, and depression status.

Eligibility criteria:
inclusion criteria: 1. aged 18 or above; 2. received single-port thoracoscopic surgery; 3. volunteered to participate in the study and signed an informed consent form. exclusion criteria: 1. presence of a mental disorder 2. preoperative pain 3. pregnancy 4. presence of other tumours requiring treatment.

Keywords: preoperative education
navitas and envision - study to characterize select objective metrics & clinical outcomes in chronic pain patients with boston scientific neurostimulation systems

Conditions: Pain, Chronic

Summary: the objective of the study is to characterize the relationship between select objective metrics and clinical outcomes in chronic pain patients treated with boston scientific commercially approved neurostimulation systems.


Eligibility criteria:
key inclusion criteria: - is willing and able to comply with completing protocol required assessments and evaluations key exclusion criteria: - has any pain-related diagnosis, medical/psychological condition or external factors that, in the investigator's medical judgment, might confound reporting of study outcomes (e.g. history of pelvic pain, anginal pain, chronic migraine, involved in litigation, workmen's compensation)
mortality and morbidity associated with new onset acute kidney injury in critically ill covid-19 infection patients

Conditions: Acute Kidney Injury

Summary: this study explored the incidence of morbidity and mortality associated with aki in critically ill adult patients infected with covid-19. there are two groups for comparison. group1. patients were directly admitted to the intensive care unit (icu) from the emergency department (ed) group 2. patients were initially managed on the medical floor and later transferred to the icu for worsening respiratory status. the investigating team evaluated the correlation of inflammatory markers and common risk factors such as obesity, diabetes, hypertension and ethnicity to the development of aki in the target population. the primary outcome is mortality participants will received their regular healthcare in a medical setting


Eligibility criteria:
inclusion criteria: positive for sars-cov-2 on a real-time polymerase chain reaction test (rt-pcr) upon admission to the hospital exclusion criteria: chronic kidney disease end stage renal disease
dry needling vs dry needling with es in patients with neck/shoulder pain

Conditions: Myofascial Pain; Neck Pain; Shoulder Pain

Summary: first, we aim to determine if there is a difference in the rate of improvement, as measured by the neck disability index (ndi) and numerical pain rating scale (nprs), across a 6 week treatment period between those treated with dn only and those treated with dn and intramuscular electrical stimulation (ies) in subjects with upper trapezius active trigger points (atrps). secondly, we want to determine if improvements in clinical outcomes (ndi and nprs) of patients with upper trapezius active trigger points (atrps) treated with dry needling (dn) alone or dry needling with intramuscular electrical stimulation (dn/ies) are maintained 6 weeks post treatment without further intervention. research questions: 1. is there a difference in the rate of improvement in ndi and nprs across a 6 week treatment period in subjects with upper trapezius active trigger points (atrps) between those treated with dn only and those treated with dn and intramuscular electrical stimulation (ies)? 2. are improvements in clinical outcomes (ndi and nprs) of patients with upper trapezius active trigger points (atrps) treated with dry needling (dn) maintained 6 weeks post treatment without further intervention? tertiary exploration: if improvement is maintained, is there a difference in outcome maintenance between groups? did improvement increase between 6 and 12 weeks?


Eligibility criteria:
inclusion criteria: 18-59 years old have an active email account have at least one palpable active trigger point (trp) (located in one or both upper trapezius) english speaking exclusion criteria: current or previous history of cancer active infection neurologic deficit cognitive deficit pregnancy connective tissue disease and/or autoimmune disorder smoke tobacco received previous dn treatments within 6 weeks of the study, experienced unilateral or bilateral neck/shoulder pain continuously for 3 months or longer
a study of hs-10342 in chinese patients with hr+/her2- advanced and/or metastatic breast cancer

Conditions: HR+/HER2- Advanced and/or Metastatic Breast Cancer

Summary: hs-10342 is a selective cdk4/6 kinase inhibitor. this study is conducted to evaluate the safety and efficacy of hs-10342 at repeated doses.

hs-10342-201 is a single- arm, open- label, multicenter, phase 2 study in patients with hormone receptor positive (hr positive), human epidermal growth factor receptor 2 negative (her2 negative) advanced and/or metastatic breast cancer who have had disease progression after endocrine therapy. the efficacy is evaluated as monotherapy, and the primary endpoint is orr.

Eligibility criteria:
inclusion criteria: 1. have a diagnosis of hormone receptor positive(hr+), human epidermal growth factor receptor 2 negative (her2-) breast cancer. 2. recurrent, locally advanced, unresectable or metastatic breast cancer with disease progression following anti-estrogen therapy. 3. prior treatment with chemotherapy regimens, no more than 2 prior chemotherapy regimens in the metastatic setting. 4. at least one extracranial measurable lesion according to response evaluation criteria in solid tumors (recist) criteria version 1.1. 5. recovered from the acute effects of therapy with toxicity resolving to baseline or grade 1 except for residual alopecia and peripheral neuropathy. 6. adequate function of major organs. exclusion criteria: 1. has received or is undergoing the following treatments: 1. currently receiving or have received any cdk4/6 inhibitors; 2. receiving/received antitumor therapy within 14 days or 5 half-lives, before the initial dose whichever is the longer; 3. radiotherapy with a limited field of radiation for palliation within 14 days of the initial dose of study drug, or received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 28 days of the initial dose.; 4. major surgery within 4 weeks of the initial dose of study drug; 5. brain metastases unless asymptomatic, stable, and not requiring steroids for at least 2 weeks prior to start of study treatment. meningeal or brainstem metastases. spinal cord compression; 2. abnormal liver and kidney functions that are known to affect drug metabolism and excretion: 3. history of other primary malignancies. 4. participating in other clinical studies.

Keywords: advanced and/or metastatic breast cancer hr+/her2- cdk4/6 hs-10342